Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia

Livio Pagano, Gina Zini, Luana Fianchi, Giovanna Rosaria Mansueto, Marianna Criscuolo, Antonia Natalina Filardi, Marco Breccia, Maria Teresa Voso, Pasquale Niscola, Alfonso Piciocchi, Luca Maurillo, Pellegrino Musto, Giovanna Mansueto, Maria Antonietta Aloe-Spiriti, Francesco Buccisano, Adriano Venditti, Andrea Tendas, Anna Lina Piccioni, Roberto Latagliata, Nunzio FilardiAlberto Fragasso, Susanna Fenu, Massimo Breccia

Risultato della ricerca: Contributo in rivistaArticolo in rivista

23 Citazioni (Scopus)

Abstract

Azacitidine is the standard of care for higher-risk myelodysplastic syndromes (MDS). We evaluated factors affecting the outcome of azacitidine treatment in 196 'real-world' patients, retrospectively collected by two Italian cooperative groups.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaEuropean Journal of Haematology
Volume2015
DOI
Stato di pubblicazionePubblicato - 2015

Keywords

  • AML
  • MDS
  • azacitidine

Fingerprint

Entra nei temi di ricerca di 'Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia'. Insieme formano una fingerprint unica.

Cita questo